The expert panel was created by the end of 2010 together between the CIHR and the MS Society of Canada. It has been proposed that the creation of this expert panel was partly directed to cope with the high levels of social pressure the CCSVI theory had raised and at the same time try to maintain a scientific perspective in the funding and investigation of CCSVI. The main task of the panel was to monitor the results of the ongoing studies in the relationship between CCSVI and MS and recommend the funding of a clinical trial in case that there was evidence of a true relationship between the two. In 2011, the Canadian federal government announced that they would fund clinical trials of the procedure to widen the veins since CIHR considered that evidence of venous abnormalities in MS was enough for small treatment trials. It has been proposed that the recommendation to fund phase I and II trials instead of a big study was a compromise between the high levels of social and political pressure and the low level of evidence on the theory.Two qualitative studies have investigated the motives and experiences of Canadian patients traveling abroad to get the "liberation procedure".
Finasteride/tadalafil, sold under the brand name Entadfi, is a fixed-dose combination medication used for the treatment of benign prostatic hyperplasia (BPH). It contains finasteride and tadalafil. It is taken by mouth.It was approved for medical use in the United States in December 2021. Medical uses
Finasteride/tadalafil is indicated to treat benign prostatic hyperplasia (BPH) in men. References
External links
"Finasteride". Drug Information Portal. U.S. National Library of Medicine. "Tadalafil". Drug Information Portal. U.S. National Library of Medicine.